Table 1.
Participant Demographic and Clinical Characteristics
| Schizophrenia (n = 39) |
Controls (n = 21) |
Test-statistic, p-value | |
|---|---|---|---|
| Age | 43.9 (11.7) | 42.6 (9.3) | F = 0.2, p= 0.65 |
| Participant Education | 13.1 (2.1) | 15.1 (1.9) | F = 14.3, p <0.001 |
| Parental Education | 13.6 (2.5) | 14.3 (2.4) | F = 0.99, p = 0.33 |
| % Male | 72% | 67% | χ2 = 0.68, p = 0.33 |
| Ethnicity | χ2 = 1.2, p = 0.77 | ||
| Caucasian | 89.7% | 95.2% | |
| African-American | 5.1% | 4.8% | |
| Native-American | 2.6% | 0.0% | |
| Bi-racial | 2.6% | 0.0% | |
| Plasma Oxytocin (pg/ml) | 24.5 (7.5) | 19.7 (5.9) | F = 6.9, p < 0.02 |
| CPZ Equivalent Dosage (mg) | 610.0 (394) | -- | -- |
| Symptoms | |||
| BNSS Total | 24.8 (17.5) | -- | -- |
| BPRS Total | 38.1 (9.6) | -- | -- |
| BPRS Positive | 2.4 (1.1) | -- | -- |
| BPRS Negative | 2.2 (1.1) | -- | -- |
| BPRS Disorganized | 1.5 (0.5) | -- | -- |
| Functional Outcome | |||
| LOF Total | 19.1 (7.7) | -- | -- |
| LOF Social | 4.7 (2.6) | -- | -- |
| LOF Work | 2.1 (2.8) | -- | -- |
Note. CPZ = Chlorpromazine Equivalent Dosage; BNSS = Brief negative Symptom Scale; BPRS = Brief Psychiatric Rating Scale; LOF = Level of Function Scale